Renee Gala
President and Chief Executive Officer
Bio:
Renee Gala is President and Chief Executive Officer and a member of the Board of Directors of Jazz Pharmaceuticals, a global biopharmaceutical company focused on developing innovative medicines for people living with rare and serious diseases.
Ms. Gala became CEO in 2025 after serving as President and Chief Operating Officer and, previously, Chief Financial Officer. Since joining Jazz in 2020, she has played a key role in the company's transformation, helping expand its portfolio and pipeline through strategic transactions and acquisitions.
Throughout her career, Ms. Gala has built a reputation for combining strategic vision, operational excellence and disciplined execution to drive growth and innovation. She has led major financings and transformative corporate development initiatives, helping organizations scale, innovate and deliver meaningful impact for patients.
Prior to joining Jazz, she served as Chief Financial Officer of GRAIL and Theravance Biopharma and held leadership roles spanning finance, strategy, business development, and commercial operations at Theravance, Eli Lilly and Company, and in the energy sector.
Today, she leads Jazz by bringing the organization together around a shared purpose: to innovate to transform the lives of patients and their families. Known for her collaborative and empowering leadership style, she encourages teams to think boldly, act decisively, and pursue Jazz's ambition to redefine what is possible for patients and their families in rare diseases through meaningful innovation.
In addition to leading Jazz, Ms. Gala serves on the Board of Directors of Dexcom. She holds a Bachelor of Science in Mathematics from Vanderbilt University and an MBA from Columbia Business School.